A Phase 3 interventional study of Rituximab and Lenalidomide in Lymphoma, Non-Hodgkin, sponsored by Celgene. Completed at 160 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-22.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing lenalidomide in Lymphoma, Non-Hodgkin — 2 open to participants now, 4 under way, 1 of them phase 3. Lenalidomide · Lymphoma, Non-Hodgkin.
Among the 32 studies testing lenalidomide in Lymphoma, Non-Hodgkin, this one is the 3rd largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2013, is one of 4 in phase 3, and was the 20th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →2 of the 32 studies testing lenalidomide in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:
University of Cologne · Sites in Germany
Ages 18–99
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
By country, each count listing its studies:
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 21 · Phase 3 5
First in 2002; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 358 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 46 across the 31 interventional studies. Of the 26 that completed or were terminated, 19 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 32 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb: 2 open now, 5 under way, none of them phase 3. Of 42 finished, 25 (60%) have results posted.
Among the 50 studies in Lymphoma, Non-Hodgkin by Bristol-Myers Squibb, this one is the 5th largest by enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2013, is one of 5 in phase 3, and was the 19th registered.
Bristol-Myers Squibb’s Lymphoma, Non-Hodgkin studies by the year they started, since 2004.
3 of the studies testing lenalidomide in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05950165Cho Pharma Inc.A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma | 2026-12-23 |
| NCT05583071University of CologneMethotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | 2027-02 |
| NCT03223610National Cancer Institute (NCI)Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | 2027-08-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing lenalidomide in Lymphoma, Non-Hodgkin, from their registry updates:
Among Bristol-Myers Squibb’s 50 in Lymphoma, Non-Hodgkin:
This tab as a report to print or save as PDF → With an account.
This double-blind randomized, parallel group study will evaluate the efficacy and safety of lenalidomide (Revlimid, CC-5013) in combination with rituximab (MabThera/Rituxan) in patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma. Patients will be randomized to receive either lenalidomide or placebo for twelve 28-day cycles in combination with rituximab. Anticipated time on study treatment is 1 year.
Indolent lymphoma is a slow growing but incurable lymphoma which includes follicular lymphoma and marginal zone lymphoma. Follicular lymphoma and marginal zone lymphoma are cancers of the B lymphocyte, a type of white blood cell. Lenalidomide is an immunomodulatory drug (a drug that affects the immune system) which alters the body's immune system and it may also interfere with the development of tiny blood vessels involved in tumor growth. Therefore, lenalidomide may reduce or prevent the growth of cancer cells. Lenalidomide has also been shown to restore the immune cells' ability to attack and kill tumor cells, an ability that may be inhibited by follicular lymphoma and other lymphomas. The combination of rituximab and lenalidomide may eliminate the cancer while restoring the immune system's ability to attack tumor cells.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received rituximab 375 mg/m\^2 intravenously (IV) every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from Cycles 2 to 5 plus lenalidomide 20 mg by mouth (PO) once daily on Days 1 to 21 every 28 days, up to 12 cycles (21-day treatment and 7-day rest period); if creatinine clearance (CrCl) was ≥ 30 mL/min but \< 60 mL/min, participants received lenalidomide 10 mg capsules on days 1 to 21 every 28 days.
Drug: Rituximab · Drug: Lenalidomide
Participants received riituximab 375 mg/m\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) and on Day 1 of every 28-day cycle from cycle 2 to 5 plus placebo (identically matched capsule) once daily on Days 1 to 21 of every 28-day cycle up, to 12 cycles.
Drug: Rituximab · Drug: Placebo
Rituximab 375mg/m\^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5
Also known as: Rituxan
Lenalidomide 20mg by mouth (PO) daily on Days 1 to 21 every 28 days up to 12 cycles
Also known as: CC-5013, Revlimid
Placebo (identical matched capsule) PO daily on Days 1 to 21 every 28 days
Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria (IWGRC)
Progression-free survival (PFS) was defined as the time from date of randomization into the study to the first observation of documented disease progression or death due to any cause, whichever occurred first. PFS was based on the data from the IRC review using the modified 2007 International Working Group Response Criteria (IWGRC) using FDA censoring rules.
Time frame: From randomization of study drug up to disease progression or death, which occurred first; up to the data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).
Durable Complete Response Rate (DCCR) as Assessed by the IRC According to the 2007 IWGRC
DCCR was defined as the percentage of participants with a best response of complete response (CR) that lasted no less than one year (≥ 48 weeks) during the study prior to administration of new anti-lymphoma therapy. A CR is defined as a complete disappearance of any disease-related symptoms and normalization of biochemical abnormalities.
Time frame: From first dose of investigational product (IP) to data cut-off date of 22 June 2018; the median treatment duration was 11.19 months in the rituximab/lenalidomiade arm and 11.04 months in the rituximab/placebo arm
Kaplan-Meier Estimate of Overall Survival (OS)
Overall survival was defined as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.
Time frame: From date of randomization to death due to any cause (Average of 55.71 months and a maximum up to 95.2 months)
Percentage of Participants With an Objective Response as Assessed by the IRC According to the 2007 IWGRC
Percentage of participants with an objective response is defined as having a response of at least a PR during the study without administration of new anti-lymphoma therapy. A complete response = a complete disappearance of all detectable clinical and radiographic evidence of disease, disappearance of any disease-related symptoms, and normalization of biochemical abnormalities; a partial response (PR) = 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD.
Time frame: From date of first dose to data cut-off date of 22 June 2018; the median treatment duration was 11.19 months in the rituximab/lenalidomide arm and 11.04 months in the rituximab/placebo arm
Percentage of Participants With a Best Response of Complete Response as Assessed by the IRC According to the 2007 IWGRC
Percentage of participants with a best response of at CR during the study without administration of new anti-lymphoma therapy. A CR = Complete disappearance of all detectable clinical and radiographic evidence of disease, disappearance of any disease-related symptoms, and normalization of biochemical abnormalities.
Time frame: From date of first dose up to data cut-off date of 22 June 2018; the median treatment duration was 11.19 months in the rituximab/lenalidomide arm and 11.04 months in the rituximab/placebo arm
Kaplan-Meier Estimate of Duration of Objective Response as Assessed by the IRC According to the 2007 IWGRC
Duration of response (DOR) was defined as the time from initial response (at least PR) until documented progressive disease (PD) or death. Participants who had not progressed at the time of analysis were censored at the last assessment date that the participant was known to be progression free. Participants who received a new treatment without documented progression were censored at the last assessment date that the participants was known to be progression free.
Time frame: From randomization up to data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).
Kaplan-Meier Estimate of Duration of Complete Response (DOCR) as Assessed by the IRC According to the 2007 IWGRC
DOCR was defined as the time from initial CR until documented PD or death. Participants who had not progressed at the time of analysis were censored at the last assessment date that the participant was known to be progression free. Participants who received a new treatment without documented progression were censored at the last assessment date that the participants was known to be progression free.
Time frame: From randomization up to data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).
Kaplan Meier Estimate of Event Free Survival as Assessed by the IRC According to the 2007 IWGRC
Event-free survival (EFS) was defined as the time from date of randomization to date of first documented progression, relapse, institution of new anti-lymphoma treatment (chemotherapy, radiotherapy or immunotherapy) or death from any cause. Responding participants and those who were lost to follow up were censored at their last tumor assessment date.
Time frame: From date of randomization to data cut-off date of 22 June 2018; overall median follow-up time for all participants was 28.30 months (range: 0.1 to 51.3 months).
Kaplan Meier Estimate of Time to Next Anti-Lymphoma Treatment (TTNLT)
Time to next anti-lymphoma treatment (TTNLT) was defined as the time from date of randomization to date of first documented administration of a new anti-lymphoma treatment (including chemotherapy, radiotherapy, radioimmunotherapy or immunotherapy). The time to the next anti-lymphoma treatment was of special interest to the study.
Time frame: From date of randomization to date of first documented administration of a new anti-lymphoma treatment (Average of 55.71 months and a maximum up to 95.2 months)
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
TEAEs include AEs that started or worsened between the date of the first dose and 28 days after the date of the last dose. A serious adverse event (SAE) is any: • Death; • Life-threatening event; • Any inpatient hospitalization or prolongation of existing hospitalization; • Persistent or significant disability or incapacity; • Congenital anomaly or birth defect; • Any other important medical event. The investigator determined the relationship of an AE to study drug based on the timing of the AE relative to drug administration and whether or not other drugs, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the event. The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.03) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death
Time frame: From first dose to 28 days post last dose (Average of 55.71 months and a maximum up to 95.2 months)
| Milestone | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo |
|---|---|---|
| Started | 178 | 180 |
| Completed | 176 | 180 |
| Not completed | 2 | 0 |
| Withdrew: Adverse event unrelated to study drug | 1 | 0 |
| Withdrew: Death | 1 | 0 |
| Milestone | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo |
|---|---|---|
| Started | 176 | 180 |
| Completed | 124 | 110 |
| Not completed | 52 | 70 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Adverse event | 14 | 8 |
| Withdrew: Progressive disease | 21 | 54 |
| Withdrew: Withdrawal by subject | 13 | 7 |
| Withdrew: Other reasons | 2 | 1 |
Progression-free survival (PFS) was defined as the time from date of randomization into the study to the first observation of documented disease progression or death due to any cause, whichever occurred first. PFS was based on the data from the IRC review using the modified 2007 International Working Group Response Criteria (IWGRC) using FDA censoring rules.
| months | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo |
|---|---|---|
| Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria (IWGRC) | 39.4 (22.9 to NA) | 14.1 (11.4 to 16.7) |
DCCR was defined as the percentage of participants with a best response of complete response (CR) that lasted no less than one year (≥ 48 weeks) during the study prior to administration of new anti-lymphoma therapy. A CR is defined as a complete disappearance of any disease-related symptoms and normalization of biochemical abnormalities.
| Percentage of Participants | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo |
|---|---|---|
| Durable Complete Response Rate (DCCR) as Assessed by the IRC According to the 2007 IWGRC | 25.3 (19.1 to 32.3) | 11.1 (6.9 to 16.6) |
Overall survival was defined as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented.
| Months | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo |
|---|---|---|
| Kaplan-Meier Estimate of Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
Percentage of participants with an objective response is defined as having a response of at least a PR during the study without administration of new anti-lymphoma therapy. A complete response = a complete disappearance of all detectable clinical and radiographic evidence of disease, disappearance of any disease-related symptoms, and normalization of biochemical abnormalities; a partial response (PR) = 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD.
| Percentage of Participants | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo |
|---|---|---|
| Percentage of Participants With an Objective Response as Assessed by the IRC According to the 2007 IWGRC | 77.5 (70.7 to 83.4) | 53.3 (45.8 to 60.8) |
Percentage of participants with a best response of at CR during the study without administration of new anti-lymphoma therapy. A CR = Complete disappearance of all detectable clinical and radiographic evidence of disease, disappearance of any disease-related symptoms, and normalization of biochemical abnormalities.
| Percentage of Participants | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo |
|---|---|---|
| Percentage of Participants With a Best Response of Complete Response as Assessed by the IRC According to the 2007 IWGRC | 33.7 (26.8 to 41.2) | 18.3 (13.0 to 24.8) |
Duration of response (DOR) was defined as the time from initial response (at least PR) until documented progressive disease (PD) or death. Participants who had not progressed at the time of analysis were censored at the last assessment date that the participant was known to be progression free. Participants who received a new treatment without documented progression were censored at the last assessment date that the participants was known to be progression free.
| months | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo |
|---|---|---|
| Kaplan-Meier Estimate of Duration of Objective Response as Assessed by the IRC According to the 2007 IWGRC | 36.6 (22.9 to NA) | 21.7 (12.8 to 27.6) |
DOCR was defined as the time from initial CR until documented PD or death. Participants who had not progressed at the time of analysis were censored at the last assessment date that the participant was known to be progression free. Participants who received a new treatment without documented progression were censored at the last assessment date that the participants was known to be progression free.
| months | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo |
|---|---|---|
| Kaplan-Meier Estimate of Duration of Complete Response (DOCR) as Assessed by the IRC According to the 2007 IWGRC | NA (25.3 to NA) | NA (13.8 to NA) |
Event-free survival (EFS) was defined as the time from date of randomization to date of first documented progression, relapse, institution of new anti-lymphoma treatment (chemotherapy, radiotherapy or immunotherapy) or death from any cause. Responding participants and those who were lost to follow up were censored at their last tumor assessment date.
| months | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo |
|---|---|---|
| Kaplan Meier Estimate of Event Free Survival as Assessed by the IRC According to the 2007 IWGRC | 27.6 (22.1 to NA) | 13.9 (11.4 to 16.7) |
Time to next anti-lymphoma treatment (TTNLT) was defined as the time from date of randomization to date of first documented administration of a new anti-lymphoma treatment (including chemotherapy, radiotherapy, radioimmunotherapy or immunotherapy). The time to the next anti-lymphoma treatment was of special interest to the study.
| Months | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo |
|---|---|---|
| Kaplan Meier Estimate of Time to Next Anti-Lymphoma Treatment (TTNLT) | 73.1 (43.0 to NA) | 31.8 (22.2 to 39.4) |
TEAEs include AEs that started or worsened between the date of the first dose and 28 days after the date of the last dose. A serious adverse event (SAE) is any: • Death; • Life-threatening event; • Any inpatient hospitalization or prolongation of existing hospitalization; • Persistent or significant disability or incapacity; • Congenital anomaly or birth defect; • Any other important medical event. The investigator determined the relationship of an AE to study drug based on the timing of the AE relative to drug administration and whether or not other drugs, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the event. The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.03) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death
| Participants | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo |
|---|---|---|
| Any TEAE | 174 | 173 |
| Any TEAE Related to Lenalidomide/Placebo (LEN/PBO) | 159 | 118 |
| Any TEAE Related to Rituximab (RIT) | 134 | 105 |
| Any Serious TEAE | 45 | 25 |
| Any Serious TEAE Related to LEN/PBO | 23 | 8 |
| Any Serious TEAE Related to RIT | 13 | 4 |
| Any CTCAE Grade (GR) 3/4 TEAE | 121 | 58 |
| Any CTCAE GR 3/4 TEAE Related to LEN/PBO | 101 | 38 |
| Any CTCAE GR 3/4 TEAE Related to RIT | 57 | 20 |
| Any GR 5 TEAE | 2 | 2 |
| Any TEAE Leading to Dose Reduction LEN/PBO | 46 | 6 |
| Any TEAE Leading to Dose Interruption LEN/PBO | 113 | 47 |
| Any TEAE Leading to Dose Interruption RIT | 59 | 38 |
| Any TEAE Leading to Discontinuation of LEN/PBO | 15 | 9 |
| Any TEAE Leading to Discontinuation of RIT | 6 | 2 |
Collected over Other (Not including Serious) Adverse Events (AEs) and Serious Adverse Events (SAEs) are collected from first dose to 28 days post last dose (Average of 55.71 months and a maximum up to 95.2 months). Participants were assessed for All-cause mortality from their date of randomization to study completion (Up to approximately 100 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab + Lenalidomide (R^2) | 27/178 (15.2%) | 45/176 (25.6%) | 170/176 (96.6%) |
| Rituximab + Placebo | 47/180 (26.1%) | 25/180 (13.9%) | 158/180 (87.8%) |
| Event | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 6/176 | 6/180 |
| Febrile neutropeniaBlood and lymphatic system disorders | 5/176 | 0/180 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/176 | 1/180 |
| NeutropeniaBlood and lymphatic system disorders | 3/176 | 0/180 |
| PyrexiaGeneral disorders | 3/176 | 0/180 |
| SepsisInfections and infestations | 3/176 | 2/180 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/176 | 3/180 |
| AnaemiaBlood and lymphatic system disorders | 2/176 | 0/180 |
| Supraventricular tachycardiaCardiac disorders | 2/176 | 0/180 |
| General physical health deteriorationGeneral disorders | 2/176 | 1/180 |
| Event | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 103/176 | 40/180 |
| DiarrhoeaGastrointestinal disorders | 55/176 | 42/180 |
| ConstipationGastrointestinal disorders | 46/176 | 25/180 |
| CoughRespiratory, thoracic and mediastinal disorders | 40/176 | 31/180 |
| FatigueGeneral disorders | 38/176 | 33/180 |
| LeukopeniaBlood and lymphatic system disorders | 37/176 | 18/180 |
| PyrexiaGeneral disorders | 35/176 | 27/180 |
| Upper respiratory tract infectionInfections and infestations | 33/176 | 23/180 |
| PruritusSkin and subcutaneous tissue disorders | 33/176 | 8/180 |
| AnaemiaBlood and lymphatic system disorders | 28/176 | 8/180 |
The intent to treat (ITT) population was defined as all participants who were randomized into the trial, regardless of whether they received investigational product (IP) or not.
| Age, Continuous(Years) | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo | Total |
|---|---|---|---|
| Mean | 62.30 ± 11.227 | 61.48 ± 11.160 | 61.89 ± 11.186 |
| Sex: Female, Male(Participants) | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo | Total |
|---|---|---|---|
| Female | 103 | 83 | 186 |
| Male | 75 | 97 | 172 |
| Ethnicity (NIH/OMB)(Participants) | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 24 | 20 | 44 |
| Not Hispanic or Latino | 147 | 158 | 305 |
| Unknown or Not Reported | 7 | 2 | 9 |
| Race/Ethnicity, Customized(Participants) | Rituximab + Lenalidomide (R^2) | Rituximab + Placebo | Total |
|---|---|---|---|
| White | 118 | 115 | 233 |
| Other Races | 54 | 64 | 118 |
| Not Collected or Reported | 6 | 1 | 7 |
Showing the first 100 of 160 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2013 to primary completion in Jun 2018, 55 months.
Results were first posted in Aug 2019, 1 year 1 month after primary completion.
Of 41 industry-sponsored phase 3 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 84. This study's 55 months is below that.
Counting every sponsor, half of 58 studies reached it within 68 months; a quarter within 43 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide